A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects
Completed
Halozyme Therapeutics
Phase 4
2005-11-01
The purpose of this research study to test the effectiveness of a study medication to
increase how fast a solution called lactated Ringer’s is absorbed when put under the skin
subcutaneously. The medication to be studied is an enzyme called hyaluronidase, and is a
human recombinant form of the enzyme. The drug company name for this medication is Hylenex.
Hylenex was currently an investigational medication at the initiation of the study, but
received FDA approval during the study. An investigational medication is a medication or
formulation of a medication that is not approved by the United States Food and Drug
Administration for use in this country but may be used in studies such as this one.
A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase
Completed
Halozyme Therapeutics
Phase 1
2007-02-01
This Phase I, randomized, double-blinded, within-subject controlled, two-way crossover study
comparing the time to inject (flow rate), safety, and tolerability of a subcutaneously (SC)
administered, viscous antibody solution of with and without human recombinant hyaluronidase
(rHuPH20) in volunteer subjects.
The study hypothesizes that the time required to complete a 20-mL SC injection of a viscous
antibody with rHuPH20 will be comparable or shorter than the time required for the injection
without rHuPH20.
Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infants and Children
Completed
Halozyme Therapeutics
Phase 4
2007-08-01
The aim of the study is to evaluate the safety, effectiveness and ease of use of
subcutaneous (SC) rehydration using HYLENEX-augmented SC infusion of fluids and electrolytes
for the rehydration of pediatric patients with mild to moderate dehydration.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
